ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Alvontech

Alvontech (ALVO)

13.48
-0.015
( -0.11% )
Updated: 11:05:58

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
13.48
Bid
13.46
Ask
13.49
Volume
11,396
13.41 Day's Range 13.61
6.70 52 Week Range 18.00
Market Cap
Previous Close
13.495
Open
13.61
Last Trade
1
@
13.46
Last Trade Time
11:05:58
Financial Volume
$ 153,567
VWAP
13.4755
Average Volume (3m)
225,238
Shares Outstanding
263,510,000
Dividend Yield
-
PE Ratio
-6.44
Earnings Per Share (EPS)
-2.09
Revenue
93.38M
Net Profit
-551.73M

About Alvontech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Luxembourg City, Luxembourg, Lux
Founded
1970
Alvontech is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker ALVO. The last closing price for Alvontech was $13.50. Over the last year, Alvontech shares have traded in a share price range of $ 6.70 to $ 18.00.

Alvontech currently has 263,510,000 shares outstanding. The market capitalization of Alvontech is $3.55 billion. Alvontech has a price to earnings ratio (PE ratio) of -6.44.

ALVO Latest News

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S...

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe...

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar...

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed...

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in...

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.161.201201201213.3213.6113.226515513.3874309CS
40.231.735849056613.2514.7613.2211683613.89129061CS
12-4.37-24.481792717117.851811.010122523814.44475685CS
264.4749.61154273039.01188.922536214.30763884CS
525.0459.71563981048.44186.714830712.98802299CS
1563.9841.89473684219.5185.211519512.04618276CS
2603.9841.89473684219.5185.211519512.04618276CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MMVMultiMetaVerse Holdings Ltd
$ 1.94
(228.37%)
81.3M
GTBPGT Biopharma Inc
$ 8.1501
(161.22%)
34.77M
TANHTantech Holdings Ltd
$ 1.3288
(102.25%)
46.26M
FFIEFaraday Future Intelligent Electric Inc
$ 1.6386
(59.09%)
364.96M
CNEYCN Energy Group Inc
$ 1.05
(57.89%)
10.56M
MTCMMTec Inc
$ 3.0189
(-56.93%)
6.02M
VIRIVirios Therapeutics Inc
$ 0.1811
(-48.46%)
2.44M
AKTSAkoustis Technologies Inc
$ 0.1852
(-48.01%)
9.26M
JAGXJaguar Health Inc
$ 0.1426
(-44.84%)
31.33M
FLJFLJ Group Limited
$ 0.9099
(-41.30%)
3.16M
CRKNCrown Electrokinetics Corporation
$ 0.1848
(8.07%)
454.38M
FFIEFaraday Future Intelligent Electric Inc
$ 1.6386
(59.09%)
364.96M
GWAVGreenwave Technology Solutions Inc
$ 0.1413
(-8.31%)
226.82M
MMVMultiMetaVerse Holdings Ltd
$ 1.94
(228.37%)
81.3M
SINTSiNtx Technologies Inc
$ 0.1019
(19.88%)
69.5M

ALVO Discussion

View Posts
Monksdream Monksdream 4 months ago
ALVO new 52 week high
👍️0
Monksdream Monksdream 4 months ago
ALVO new 52=week high
👍️0
Liquid_Bull Liquid_Bull 1 year ago
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13 2023 - 08:45PM
GlobeNewswire Inc

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved. No other deficiencies in the application were noted by the FDA. Alvotech provided the FDA comprehensive responses to the inspection observations on April 3, 2023, and is awaiting communication from the agency assessing those responses.
Alvotech’s second BLA for AVT02, which contains data to support approval as a biosimilar and additional information supporting potential interchangeability designation – remains under review by the FDA, with a Biosimilar User Fee Amendment (BsUFA) goal date of June 28, 2023. Satisfactory outcome of the facility reinspection remains the key requirement for approval.

“We look forward to working with the FDA to resolve any outstanding issues identified in the reinspection,” said Robert Wessman, Chairman and CEO of Alvotech. “We are committed to manufacturing AVT02 for patients in the United States, especially a potentially differentiated Humira biosimilar that provides a high-concentration formulation and is interchangeable.”

About AVT02
AVT02 is a monoclonal antibody and has been approved as a biosimilar to Humira® (adalimumab) in the 27 EU member countries, Norway, Lichtenstein, Iceland, the UK, Switzerland, Canada, Australia and Saudi Arabia. It is currently marketed in sixteen countries in Europe and in Canada. Dossiers are under review in multiple countries, including in the United States.

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
👍️0
Liquid_Bull Liquid_Bull 1 year ago
Just to be clear the company name is ALVOTECH not alvoNtech which was an error while creating the board. I will fix it asap. The stock symbol is ALVO
👍️0
Liquid_Bull Liquid_Bull 1 year ago
Alvotech

https://www.alvotech.com/

We have a deep appreciation for the positive impact biologic medicines have had on health care. From insulin to vaccines to monoclonal antibody cancer therapies, biologic medicines are revolutionizing the way we treat diseases and improve patient lives.

It is our aim to broaden the availability of these important biologic medicines to patients around the world by developing and manufacturing high-quality, cost-competitive biosimilars.

Our commitment to the promise of biosimilars is foundational to our approach, our culture and the strong sense of purpose that inspires us to work smarter and faster towards this mission.

We are driven by passion - if there is a proven biologic medicine, we believe it should be accessible to all patients in need.
👍️0

Your Recent History

Delayed Upgrade Clock